



Clinical trial results:

Evaluation of the antiseptic activity of 4 different modes of application of a 5% alcoholic povidone-iodine product (Bétadine® Alcoolique 5%)

Summary

| | |
|--------------------------|-------------------|
| EudraCT number | 2019-000694-24 |
| Trial protocol | FR |
| Global end of trial date | 07 September 2020 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 06 November 2021 |
| First version publication date | 06 November 2021 |

Trial information

Trial identification

| | |
|-----------------------|--------------|
| Sponsor protocol code | X-00069-3322 |
|-----------------------|--------------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Meda Pharma GmbH & Co. KG (A Mylan company) |
| Sponsor organisation address | Benzstraße 1, Bad Homburg, Germany, 61352 |
| Public contact | Clinical Affairs GKB, Meda Pharma GmbH & Co. KG (A Mylan company), 49 61728881425, susanne.horner@viatris.com |
| Scientific contact | Clinical Affairs GKB, Meda Pharma GmbH & Co. KG (A Mylan company), 49 61728881425, susanne.horner@viatris.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 23 October 2020 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 07 September 2020 |
| Global end of trial reached? | Yes |
| Global end of trial date | 07 September 2020 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this clinical trial is to evaluate the antiseptic activity of a 5% alcoholic povidone-iodine solution (Bétadine® Alcoolique 5%) applied with 4 different modes of application

Protection of trial subjects:

Study involved topical application of the medication over a specific period up to 30 mins, post which the application was rinsed off with soap and water. No specific additional measures were required to minimize distress given the nature of study. The subjects were provided with informed consents prior to start of any study procedures. Subjects could withdraw from treatment at any time and for any reason.

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 22 June 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | France: 32 |
| Worldwide total number of subjects | 32 |
| EEA total number of subjects | 32 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 31 |
| From 65 to 84 years | 1 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Main study started after the confirmation of the method validation. An in-vitro and an in-vivo formed method validation.

For the in-vivo validation, 20 subjects in addition to subjects in the main study were included and In-vivo recruitment started on 02 Sep 2019.

Main study had 32 subjects and recruitment for main study started on 22 Jun 2020.

Pre-assignment

Screening details:

Healthy male and non-pregnant females (including non-pregnant females of child-bearing potential using acceptable methods of contraception) aged between 18 and 65 years (inclusive), with a BMI ≤ 30 , having adequate back size to cover 4 application fields of 10 x 10 cm, having a minimum CFU count of 2.5 log₁₀/cm² at screening visit.

Pre-assignment period milestones

| | |
|--|----------------|
| Number of subjects started | 32 |
| Intermediate milestone: Number of subjects | Main study: 32 |
| Number of subjects completed | 32 |

Period 1

| | |
|------------------------------|-----------------------------------|
| Period 1 title | Main study: Baseline CFU sampling |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--------------------------|
| Are arms mutually exclusive? | No |
| Arm title | Baseline CFU Treatment A |

Arm description:

Baseline CFU sampling for treatment A: 3 mL Bétadine® Alcoolique 5% applied in spiral movement starting in the center of a 10 x 10 cm zone (snailing method, 3 mL)

| | |
|--|-------------------------|
| Arm type | Baseline sampling |
| Investigational medicinal product name | Bétadine® Alcoolique 5% |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cutaneous solution |
| Routes of administration | Cutaneous use |

Dosage and administration details:

Before baseline sampling, no product has been applied.

| | |
|------------------|--------------------------|
| Arm title | Baseline CFU Treatment B |
|------------------|--------------------------|

Arm description:

Baseline CFU for treatment B: 10 mL Bétadine® Alcoolique 5% applied in spiral movement starting in the center of a 10 x 10 cm zone (snailing method, 10 mL)

| | |
|----------|-------------------|
| Arm type | Baseline sampling |
|----------|-------------------|

| | |
|--|--------------------------|
| Investigational medicinal product name | Bétadine® Alcoolique 5% |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cutaneous solution |
| Routes of administration | Cutaneous use |
| Dosage and administration details: | |
| Before baseline sampling, no product has been applied. | |
| Arm title | Baseline CFU Treatment C |

Arm description:

Baseline CFU sampling for treatment C: 3 mL Bétadine® Alcoolique 5% applied by back and forth movements horizontally and vertically covering a 10 x 10 cm zone (scraping method, 3 mL)

| | |
|--|--------------------------|
| Arm type | Baseline sampling |
| Investigational medicinal product name | Bétadine® Alcoolique 5% |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cutaneous solution |
| Routes of administration | Cutaneous use |
| Dosage and administration details: | |
| Before baseline sampling, no product has been applied. | |
| Arm title | Baseline CFU Treatment D |

Arm description:

Baseline CFU sampling for Treatment D: 10 mL Bétadine® Alcoolique 5% applied by back and forth movements horizontally and vertically covering a 10 x 10 cm zone (scraping method, 10 mL).

| | |
|--|-------------------------|
| Arm type | Baseline sampling |
| Investigational medicinal product name | Bétadine® Alcoolique 5% |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cutaneous solution |
| Routes of administration | Cutaneous use |
| Dosage and administration details: | |
| Before baseline sampling, no product has been applied. | |
| Investigational medicinal product name | Bétadine® Alcoolique 5% |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cutaneous solution |
| Routes of administration | Cutaneous use |

Dosage and administration details:

Before baseline sampling, no product has been applied.

| Number of subjects in period 1 | Baseline CFU Treatment A | Baseline CFU Treatment B | Baseline CFU Treatment C |
|---------------------------------------|--------------------------|--------------------------|--------------------------|
| Started | 32 | 32 | 32 |
| Completed | 32 | 32 | 32 |

| Number of subjects in period 1 | Baseline CFU Treatment D |
|---------------------------------------|--------------------------|
| Started | 32 |

| | |
|-----------|----|
| Completed | 32 |
|-----------|----|

Period 2

| | |
|------------------------------|---|
| Period 2 title | Main study: Post-Treatment CFU sampling |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--------------|
| Are arms mutually exclusive? | No |
| Arm title | Treatment A: |

Arm description:

3 mL Bétadine® Alcoolique 5% applied in spiral movement starting in the center of a 10 x 10 cm zone (snailing method, 3 mL)

| | |
|--|-------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Bétadine® Alcoolique 5% |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cutaneous solution |
| Routes of administration | Cutaneous use |

Dosage and administration details:

3 mL Bétadine® Alcoolique 5% applied in spiral movement starting in the center of a 10 x 10 cm zone (snailing method, 3 mL),

| | |
|------------------|-------------|
| Arm title | Treatment B |
|------------------|-------------|

Arm description:

10 mL Bétadine® Alcoolique 5% applied in spiral movement starting in the center of a 10 x 10 cm zone (snailing method, 10 mL)

| | |
|--|-------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Bétadine® Alcoolique 5% |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cutaneous solution |
| Routes of administration | Cutaneous use |

Dosage and administration details:

10 mL Bétadine® Alcoolique 5% applied in spiral movement starting in the center of a 10 x 10 cm zone (snailing method, 10 mL)

| | |
|------------------|-------------|
| Arm title | Treatment C |
|------------------|-------------|

Arm description:

3 mL Bétadine® Alcoolique 5% applied by back and forth movements horizontally and vertically covering a 10 x 10 cm zone (scrapping method, 3 mL)

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|-------------------------|
| Investigational medicinal product name | Bétadine® Alcoolique 5% |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cutaneous solution |
| Routes of administration | Cutaneous use |

Dosage and administration details:

3 mL Bétadine® Alcoolique 5% applied by back and forth movements horizontally and vertically covering a 10 x 10 cm zone (scraping method, 3 mL)

| | |
|------------------|-------------|
| Arm title | Treatment D |
|------------------|-------------|

Arm description:

10 mL Bétadine® Alcoolique 5% applied by back and forth movements horizontally and vertically covering a 10 x 10 cm zone (scraping method, 10 mL)

| | |
|--|-------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Bétadine® Alcoolique 5% |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cutaneous solution |
| Routes of administration | Cutaneous use |

Dosage and administration details:

10 mL Bétadine® Alcoolique 5% applied by back and forth movements horizontally and vertically covering a 10 x 10 cm zone (scraping method, 10 mL)

| Number of subjects in period 2 | Treatment A: | Treatment B | Treatment C |
|---------------------------------------|--------------|-------------|-------------|
| Started | 32 | 32 | 32 |
| Completed | 32 | 32 | 32 |

| Number of subjects in period 2 | Treatment D |
|---------------------------------------|-------------|
| Started | 32 |
| Completed | 32 |

Baseline characteristics

Reporting groups

| | |
|--------------------------------|-----------------------------------|
| Reporting group title | Main study: Baseline CFU sampling |
| Reporting group description: - | |

| Reporting group values | Main study: Baseline CFU sampling | Total | |
|---|-----------------------------------|-------|--|
| Number of subjects | 32 | 32 | |
| Age categorical | | | |
| Healthy male and/or female subjects aged between 18 and 65 years (inclusive). | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 31 | 31 | |
| From 65-84 years | 1 | 1 | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 18 | 18 | |
| Male | 14 | 14 | |

Subject analysis sets

| | |
|--|---------------------------------|
| Subject analysis set title | Change of CFU count treatment A |
| Subject analysis set type | Per protocol |
| Subject analysis set description: | |
| Change of CFU count (in log10/cm2) from baseline -Treatment A (3 mL, Snail) | |
| Subject analysis set title | Change of CFU count treatment B |
| Subject analysis set type | Per protocol |
| Subject analysis set description: | |
| Change of CFU count (in log10/cm2) from baseline - Treatment B (10 mL, Snail) | |
| Subject analysis set title | Change of CFU count treatment C |
| Subject analysis set type | Per protocol |
| Subject analysis set description: | |
| Change of CFU count (in log10 /cm2) from baseline - Treatment C (3mL, Scrape) | |
| Subject analysis set title | Change of CFU count treatment D |
| Subject analysis set type | Per protocol |
| Subject analysis set description: | |
| Change of CFU count (in log10 /cm2) from baseline - Treatment D (10mL, Scrape) | |

| Reporting group values | Change of CFU count treatment A | Change of CFU count treatment B | Change of CFU count treatment C |
|---|---------------------------------|---------------------------------|---------------------------------|
| Number of subjects | 26 | 25 | 27 |
| Age categorical | | | |
| Healthy male and/or female subjects aged between 18 and 65 years (inclusive). | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 25 | 24 | 26 |
| From 65-84 years | 1 | 1 | 1 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | | | |
| Male | | | |

| | | | |
|---|------------------------------------|--|--|
| Reporting group values | Change of CFU count treatment D | | |
| Number of subjects | 27 | | |
| Age categorical | | | |
| Healthy male and/or female subjects aged between 18 and 65 years (inclusive). | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 26 | | |
| From 65-84 years | 1 | | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | | | |
| Male | | | |

End points

End points reporting groups

| | |
|---|---------------------------------|
| Reporting group title | Baseline CFU Treatment A |
| Reporting group description: Baseline CFU sampling for treatment A: 3 mL Bétadine® Alcoolique 5% applied in spiral movement starting in the center of a 10 x 10 cm zone (snailing method, 3 mL) | |
| Reporting group title | Baseline CFU Treatment B |
| Reporting group description: Baseline CFU for treatment B: 10 mL Bétadine® Alcoolique 5% applied in spiral movement starting in the center of a 10 x 10 cm zone (snailing method, 10 mL) | |
| Reporting group title | Baseline CFU Treatment C |
| Reporting group description: Baseline CFU sampling for treatment C: 3 mL Bétadine® Alcoolique 5% applied by back and forth movements horizontally and vertically covering a 10 x 10 cm zone (scraping method, 3 mL) | |
| Reporting group title | Baseline CFU Treatment D |
| Reporting group description: Baseline CFU sampling for Treatment D: 10 mL Bétadine® Alcoolique 5% applied by back and forth movements horizontally and vertically covering a 10 x 10 cm zone (scraping method, 10 mL). | |
| Reporting group title | Treatment A: |
| Reporting group description: 3 mL Bétadine® Alcoolique 5% applied in spiral movement starting in the center of a 10 x 10 cm zone (snailing method, 3 mL) | |
| Reporting group title | Treatment B |
| Reporting group description: 10 mL Bétadine® Alcoolique 5% applied in spiral movement starting in the center of a 10 x 10 cm zone (snailing method, 10 mL) | |
| Reporting group title | Treatment C |
| Reporting group description: 3 mL Bétadine® Alcoolique 5% applied by back and forth movements horizontally and vertically covering a 10 x 10 cm zone (scraping method, 3 mL) | |
| Reporting group title | Treatment D |
| Reporting group description: 10 mL Bétadine® Alcoolique 5% applied by back and forth movements horizontally and vertically covering a 10 x 10 cm zone (scraping method, 10 mL) | |
| Subject analysis set title | Change of CFU count treatment A |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Change of CFU count (in log ₁₀ /cm ²) from baseline -Treatment A (3 mL, Snail) | |
| Subject analysis set title | Change of CFU count treatment B |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Change of CFU count (in log ₁₀ /cm ²) from baseline - Treatment B (10 mL, Snail) | |
| Subject analysis set title | Change of CFU count treatment C |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Change of CFU count (in log ₁₀ /cm ²) from baseline - Treatment C (3mL, Scrape) | |
| Subject analysis set title | Change of CFU count treatment D |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Change of CFU count (in log ₁₀ /cm ²) from baseline - Treatment D (10mL, Scrape) | |

Primary: Antiseptic activity of Bétadine® Alcoolique

| | |
|-----------------|---|
| End point title | Antiseptic activity of Bétadine® Alcoolique |
|-----------------|---|

End point description:

The primary endpoints were defined as follows:

Evaluation of antiseptic activity of a 5% alcoholic povidone-iodine solution (Bétadine® Alcoolique 5%) by measuring the change from baseline in log10/cm2 CFU counts for total aerobic and facultative anaerobic bacteria using 4 different modes of applications.

Results are presented for per protocol population.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline sampling and post-treatment sampling for all 4 modes of application were collected during Visit 1.

| End point values | Baseline CFU Treatment A | Treatment A: | Baseline CFU Treatment B | Treatment B |
|-------------------------------|--------------------------|-----------------|--------------------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 26 | 26 | 25 | 27 |
| Units: CFU | | | | |
| log mean (standard deviation) | 3.473 (± 0.714) | 0.351 (± 0.796) | 3.391 (± 0.719) | 0.066 (± 0.463) |

| End point values | Baseline CFU Treatment C | Treatment C | Baseline CFU Treatment D | Treatment D |
|-------------------------------|--------------------------|-----------------|--------------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 27 | 27 | 27 | 27 |
| Units: CFU | | | | |
| log mean (standard deviation) | 3.594 (± 0.747) | 0.104 (± 0.629) | 3.450 (± 0.820) | -0.013 (± 0.535) |

| End point values | Change of CFU count treatment A | Change of CFU count treatment B | Change of CFU count treatment C | Change of CFU count treatment D |
|-------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 26 | 25 | 27 | 27 |
| Units: CFU | | | | |
| log mean (standard deviation) | -3.122 (± 0.779) | -3.339 (± 0.715) | -3.491 (± 0.605) | -3.463 (± 0.749) |

Statistical analyses

| | |
|----------------------------|--|
| Statistical analysis title | Inferential analysis - Treatment A (3 mL, Snail) |
|----------------------------|--|

Statistical analysis description:

Covariate adjusted change in log10 CFU/cm2 count from baseline - Treatment A (3mL, Snail)

| | |
|-------------------|---|
| Comparison groups | Baseline CFU Treatment A v Treatment A: |
|-------------------|---|

| | |
|---|----------------------------|
| Number of subjects included in analysis | 52 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[1] |
| P-value | ≤ 0.1 |
| Method | Mixed models analysis |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| Variability estimate | Standard error of the mean |

Notes:

[1] - 26 subjects were analyzed for log10 CFU count as part of baseline on A and 26 subjects subjects were analyzed for log10 CFU count as part of post treatment on A, giving 52 observations. Analysis was based on 26 subjects due to the cross-over design.

| | |
|--|---|
| Statistical analysis title | Inferential analysis - Treatment B (10 mL, Snail) |
| Statistical analysis description: | |
| Covariate adjusted change in log10 CFU/cm2 count from baseline - Treatment B (10mL, Snail) | |
| Comparison groups | Baseline CFU Treatment B v Treatment B |
| Number of subjects included in analysis | 52 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[2] |
| P-value | ≤ 0.1 |
| Method | Mixed models analysis |
| Parameter estimate | Mean difference (net) |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| Variability estimate | Standard error of the mean |

Notes:

[2] - 25 subjects were analyzed for log10 CFU count as part of baseline on B and 27 subjects subjects were analyzed for log10 CFU count as part of post treatment on B, giving 52 observations. Analysis was based on 25 subjects due to the cross-over design.

| | |
|--|--|
| Statistical analysis title | Inferential analysis - Treatment C (3mL, Scrape) |
| Statistical analysis description: | |
| Covariate adjusted change in log10 CFU/cm2 count from baseline - Treatment C (3mL, Scrape) | |
| Comparison groups | Baseline CFU Treatment C v Treatment C |
| Number of subjects included in analysis | 54 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[3] |
| P-value | ≤ 0.1 |
| Method | Mixed models analysis |
| Parameter estimate | Mean difference (net) |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| Variability estimate | Standard error of the mean |

Notes:

[3] - 27 subjects were analyzed for log10 CFU count as part of baseline on C and 27 subjects subjects were analyzed for log10 CFU count as part of post treatment on C, giving 54 observations. Analysis was based on 27 subjects due to the cross-over design.

| | |
|-----------------------------------|---|
| Statistical analysis title | Inferential analysis - Treatment D (10mL, Scrape) |
|-----------------------------------|---|

Statistical analysis description:

Covariate adjusted change in log10 CFU/cm2 count from baseline - Treatment D (10mL, Scrape)

| | |
|---|--|
| Comparison groups | Baseline CFU Treatment D v Treatment D |
| Number of subjects included in analysis | 54 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[4] |
| P-value | ≤ 0.1 |
| Method | Mixed models analysis |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| Variability estimate | Standard error of the mean |

Notes:

[4] - 27 subjects were analyzed for log10 CFU count as part of baseline on D and 27 subjects were analyzed for log10 CFU count as part of post treatment on D, giving 54 observations. Analysis was based on 27 subjects due to the cross-over design.

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Inferential analysis - A vs. B |
|-----------------------------------|--------------------------------|

Statistical analysis description:

Covariate adjusted change in log10 CFU/cm2 count from baseline - A vs. B (3 mL vs. 10 mL for Snail)

| | |
|---|---|
| Comparison groups | Change of CFU count treatment A v Change of CFU count treatment B |
| Number of subjects included in analysis | 51 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[5] |
| P-value | ≤ 0.1 |
| Method | Mixed models analysis |
| Parameter estimate | Mean difference (net) |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| Variability estimate | Standard error of the mean |

Notes:

[5] - 26 subjects were analyzed for change from baseline on A and 25 subjects were analyzed for change from baseline on B giving 51 observations. Analysis was based on 25 subjects due to the crossover design.

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Inferential analysis - C vs. D |
|-----------------------------------|--------------------------------|

Statistical analysis description:

Covariate adjusted change in log10 CFU/cm2 count from baseline - C vs. D (3 mL vs. 10 mL for Scrape)

| | |
|---|---|
| Comparison groups | Change of CFU count treatment C v Change of CFU count treatment D |
| Number of subjects included in analysis | 54 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[6] |
| P-value | ≤ 0.1 |
| Method | Mixed models analysis |
| Parameter estimate | Mean difference (net) |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| Variability estimate | Standard error of the mean |

Notes:

[6] - 27 subjects were analyzed for change from baseline on C and 27 subjects were analyzed for change from baseline on D giving 54 observations. Analysis was based on 27 subjects due to the crossover design.

| | |
|--|---|
| Statistical analysis title | Inferential analysis - A vs. C |
| Statistical analysis description: | |
| Covariate adjusted change in log10 CFU/cm2 count from baseline - A vs. C (Snail vs. Scrape, 3mL) | |
| Comparison groups | Change of CFU count treatment A v Change of CFU count treatment C |
| Number of subjects included in analysis | 53 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[7] |
| P-value | ≤ 0.1 |
| Method | Mixed models analysis |
| Parameter estimate | Mean difference (net) |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| Variability estimate | Standard error of the mean |

Notes:

[7] - 26 subjects were analyzed for change from baseline on A and 27 subjects were analyzed for change from baseline on C giving 53 observations. Analysis was based on 26 subjects due to the crossover design.

| | |
|--|---|
| Statistical analysis title | Inferential analysis - B vs. D |
| Statistical analysis description: | |
| 25 subjects were analyzed for change from baseline on B and 27 subjects were analyzed for change from baseline on D giving 52 observations. Analysis was based on 25 subjects due to the crossover design. | |
| Comparison groups | Change of CFU count treatment B v Change of CFU count treatment D |
| Number of subjects included in analysis | 52 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[8] |
| P-value | ≤ 0.1 |
| Method | Mixed models analysis |
| Parameter estimate | Mean difference (net) |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| Variability estimate | Standard error of the mean |

Notes:

[8] - 25 subjects were analyzed for change from baseline on B and 27 subjects were analyzed for change from baseline on D giving 52 observations. Analysis was based on 25 subjects due to the crossover design.

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

Subjects were monitored for any Adverse event from signing of the informed consent until D1 treatment visit. All AEs that occurred after the first dose of study medication through 30 days after the last dose were considered to be treatment emergent AEs

Adverse event reporting additional description:

Subjects were routinely queried regarding presence or absence of adverse events using open ended questions. Laboratory tests and Physical examinations were also undertaken. Date, time of assessment and the outcome were recorded.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 23.0 |
|--------------------|------|

Frequency threshold for reporting non-serious adverse events: 0 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: During this study neither non-serious nor serious adverse events occurred.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported